Down-regulation of Osteopontin Mediates a Novel Mechanism Underlying the Cytostatic Activity of TGF-β

Overview

Journal Cell Oncol (Dordr)

Publisher Springer

Date 2015 Nov 21

PMID 26584547

Citations 6

Authors

Jing Zhang

Osamu Yamada

Shinya Kida

Yoshihisa Matsushita

Toshio Hattori

Affiliations

Soon will be listed here.

Abstract

Purpose: Loss of a cytostatic response to TGF-β has been implicated in multiple hyper-proliferative disorders, including cancer. Although several key genes involved in the cytostatic activity of TGF-β have in the past been identified, its exact mode of action is yet to be elucidated. A comprehensive understanding of the mechanisms underlying the cytostatic activity of TGF-β may open up new avenues for the development of therapeutic strategies.

Methods: Quantitative real-time RT-PCR was used to assess osteopontin (OPN) gene expression in human hepatoma-derived Huh-7 and lung adenocarcinoma-derived A549 cells. Reporter assays using an OPN promoter-luciferase construct and its mutated counterparts were performed to assess its transcriptional activity. Binding of Smad4 to the OPN gene promoter was investigated using chromatin immunoprecipitation (CHIP). The putative role of Smad4 in OPN gene expression down-regulation was also assessed using a shRNA-mediated knockdown strategy. The anti-proliferative effect of TGF-β on different cancer-derived cell lines was determined using the cell proliferation reagent WST-1.

Results: We found that the OPN expression levels dose-dependently decreased in TGF-β-treated Huh-7 and A549 cells. Our reporter assays indicated that this TGF-β-induced repression occurred at the transcriptional level, and could largely be abrogated by disruption of an element (TIE2) similar to the TGF-β inhibitory element found in other TGF-β-repressed genes. Our CHIP assay revealed that the Smad protein complex specifically binds to the OPN gene promoter, and that the TGF-β-mediated inhibition of OPN was lost upon shRNA-mediated knockdown of Smad4. Moreover, we found that the deregulation of OPN gene expression by TGF-β occurred concomitantly with loss of the TGF-β anti-proliferative response, whereas a neutralizing anti-OPN antibody partially restored this response.

Conclusions: Our results indicate that the OPN gene is a direct target of Smad-mediated TGF-β signaling, implying that OPN expression inhibition serves as a novel mechanism underlying the cytostatic activity of TGF-β.

Citing Articles

Enoyl coenzyme a hydratase 1 attenuates aortic valve calcification by suppressing Runx2 via Wnt5a/Ca pathway.

Rao C, Liu B, Qin H, Du Z J Cell Commun Signal. 2024; 18(2):e12038.

PMID: 38946717 PMC: 11208118. DOI: 10.1002/ccs3.12038.

BET inhibitor suppresses melanoma progression the noncanonical NF-κB/SPP1 pathway.

Deng G, Zeng F, Su J, Zhao S, Hu R, Zhu W Theranostics. 2020; 10(25):11428-11443.

PMID: 33052224 PMC: 7546000. DOI: 10.7150/thno.47432.

Osteopontin as a Link between Inflammation and Cancer: The Thorax in the Spotlight.

Lamort A, Giopanou I, Psallidas I, Stathopoulos G Cells. 2019; 8(8).

PMID: 31382483 PMC: 6721491. DOI: 10.3390/cells8080815.

Microcalcification and BMP-2 in breast cancer: correlation with clinicopathological features and outcomes.

Zhang L, Hao C, Wu Y, Zhu Y, Ren Y, Tong Z Onco Targets Ther. 2019; 12:2023-2033.

PMID: 30936719 PMC: 6421899. DOI: 10.2147/OTT.S187835.

Induction of Osteopontin by Dengue Virus-3 Infection in THP-1 Cells: Inhibition of the Synthesis by Brefelamide and Its Derivative.

Pascapurnama D, Labayo H, Dapat I, Nagarajegowda D, Zhao J, Zhang J Front Microbiol. 2017; 8:521.

PMID: 28405192 PMC: 5370276. DOI: 10.3389/fmicb.2017.00521.

References

Kang J, Alliston T, Delston R, Derynck R . Repression of Runx2 function by TGF-beta through recruitment of class II histone deacetylases by Smad3. EMBO J. 2005; 24(14):2543-55. PMC: 1176457. DOI: 10.1038/sj.emboj.7600729. View

Johnston N, Gunasekharan V, Ravindranath A, OConnell C, Johnston P, El-Tanani M . Osteopontin as a target for cancer therapy. Front Biosci. 2008; 13:4361-72. DOI: 10.2741/3009. View

Maier A, Peille A, Vuaroqueaux V, Lahn M . Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts. Cell Oncol (Dordr). 2015; 38(2):131-44. PMC: 4412926. DOI: 10.1007/s13402-014-0210-8. View

Alliston T, Choy L, Ducy P, Karsenty G, Derynck R . TGF-beta-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation. EMBO J. 2001; 20(9):2254-72. PMC: 125448. DOI: 10.1093/emboj/20.9.2254. View

Scandura J, Boccuni P, Massague J, Nimer S . Transforming growth factor beta-induced cell cycle arrest of human hematopoietic cells requires p57KIP2 up-regulation. Proc Natl Acad Sci U S A. 2004; 101(42):15231-6. PMC: 524079. DOI: 10.1073/pnas.0406771101. View

Rangaswami H, Bulbule A, Kundu G . Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol. 2006; 16(2):79-87. DOI: 10.1016/j.tcb.2005.12.005. View

Shi X, Bai S, Li L, Cao X . Hoxa-9 represses transforming growth factor-beta-induced osteopontin gene transcription. J Biol Chem. 2000; 276(1):850-5. DOI: 10.1074/jbc.M005955200. View

Xu J, Lamouille S, Derynck R . TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 2009; 19(2):156-72. PMC: 4720263. DOI: 10.1038/cr.2009.5. View

Zhang J, Yamada O, Matsushita Y, Chagan-Yasutan H, Hattori T . Transactivation of human osteopontin promoter by human T-cell leukemia virus type 1-encoded Tax protein. Leuk Res. 2009; 34(6):763-8. DOI: 10.1016/j.leukres.2009.08.028. View

10.

Zhang J, Yamada O, Kida S, Matsushita Y, Yamaoka S, Chagan-Yasutan H . Identification of CD44 as a downstream target of noncanonical NF-κB pathway activated by human T-cell leukemia virus type 1-encoded Tax protein. Virology. 2011; 413(2):244-52. DOI: 10.1016/j.virol.2011.02.021. View

11.

Massague J . TGFbeta in Cancer. Cell. 2008; 134(2):215-30. PMC: 3512574. DOI: 10.1016/j.cell.2008.07.001. View

12.

Wakefield L, Roberts A . TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev. 2002; 12(1):22-9. DOI: 10.1016/s0959-437x(01)00259-3. View

13.

Hullinger T, Pan Q, Viswanathan H, Somerman M . TGFbeta and BMP-2 activation of the OPN promoter: roles of smad- and hox-binding elements. Exp Cell Res. 2000; 262(1):69-74. DOI: 10.1006/excr.2000.5074. View

14.

Massague J . TGFβ signalling in context. Nat Rev Mol Cell Biol. 2012; 13(10):616-30. PMC: 4027049. DOI: 10.1038/nrm3434. View

15.

Siegel P, Massague J . Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer. 2003; 3(11):807-21. DOI: 10.1038/nrc1208. View

16.

Matsuura M, Suzuki T, Suzuki M, Tanaka R, Ito E, Saito T . Statin-mediated reduction of osteopontin expression induces apoptosis and cell growth arrest in ovarian clear cell carcinoma. Oncol Rep. 2010; 25(1):41-7. View

17.

Lebrin F, Deckers M, Bertolino P, Ten Dijke P . TGF-beta receptor function in the endothelium. Cardiovasc Res. 2005; 65(3):599-608. DOI: 10.1016/j.cardiores.2004.10.036. View

18.

Hannon G, Beach D . p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature. 1994; 371(6494):257-61. DOI: 10.1038/371257a0. View

19.

Roberts A, Wakefield L . The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci U S A. 2003; 100(15):8621-3. PMC: 166359. DOI: 10.1073/pnas.1633291100. View

20.

Kang Y, Chen C, Massague J . A self-enabling TGFbeta response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells. Mol Cell. 2003; 11(4):915-26. DOI: 10.1016/s1097-2765(03)00109-6. View